COVID-19 - January 12, 2021
New in vitro study results about Pfizer/BioNTech’s COVID-19 vaccine
Pfizer and BioNTech have announced results from an in vitro study that shows the antibodies from people who have received their vaccine effectively neutralize SARS-CoV-2 with a key mutation that is also found in two highly transmissible strains. The results were published on the preprint server bioRxiv. Variants of SARS-CoV-2 Rapidly spreading variants of SARS-CoV-2 […]
COVID-19 - January 10, 2021
Production and supply – A logistics challenge
The manufacturing, packaging and transportation of COVID-19 vaccines requires a smooth, effective and safe supply chain. Time is of the essence, and the pharma industry supply chain is facing big logistics challenges. In record time the global life science industry has been able to discover and develop one vaccine approved for full use, six vaccines […]
COVID-19 - December 4, 2020
Pfizer and BioNTech achieve first authorization in the world for a COVID-19 vaccine
Pfizer and BioNTech have announced that the Medicines & Healthcare Products Regulatory Agency (MHRA) in the UK has granted a temporary authorization for emergency use for their mRNA vaccine (BNT162b2), against COVID-19. This constitutes the first Emergency Use Authorization following a worldwide Phase 3 trial of a vaccine to help fight the pandemic. Pfizer and […]
COVID-19 - November 9, 2020
Exclusive interview: Mikael Dolsten, Chief Scientific Officer, Pfizer
The days are busy for Sweden’s Mikael Dolsten. As head of Pfizer’s R&D he is at the scientific forefront of the fight against the COVID-19 pandemic. Scientists and researchers across the globe are racing as never before to find treatments and a vaccine for the new coronavirus that has killed more than half a million […]
COVID-19 - November 9, 2020
Promising results from Pfizer and BioNTech’s vaccine trial
Pfizer and BioNTech have announced that their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study. The […]
COVID-19 - August 4, 2020
Early positive update from Pfizer and BioNTech vaccine study
BioNTech and Pfizer has announced initial data from their ongoing German Phase 1/2, open-label, non-randomized, non-placebo-controlled, dose-escalation trial, that is part of the global mRNA-based vaccine program against SARS-CoV-2. The data are available on an online preprint server at medRxiv and are concurrently undergoing scientific peer-review for potential publication. Preliminary data The preliminary clinical results are for […]
